Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation

Case Reports in Oncology

Volumn 10, Issue 2, 2017, Pages 548-552

  Ang, Celina ^a   Stollman, Aryeh ^a   Zhu, Hongfa ^a   Sarpel, Umut ^a   Scarborough, Bethann ^a   Sahni, Gagan ^a   Millis, Sherri Z ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

Appendiceal adenocarcinoma; GNAS mutation; Targeted therapy; Trametinib

Indexed keywords

B RAF KINASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MORPHINE SULFATE; MUTL PROTEIN HOMOLOG 1; PROTEIN MSH2; PROTEIN MSH6; TRAMETINIB; TRANSCRIPTION FACTOR CDX2;

ABDOMINAL DISTENSION; ADENOCARCINOMA; ADULT; APPENDIX TUMOR; ARTICLE; CARCINOMATOUS PERITONITIS; CASE REPORT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; ECHOCARDIOGRAPHY; GENE MUTATION; GNAS R201H MUTATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RADIONUCLIDE VENTRICULOGRAPHY;

EID: 85021052759     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000477562     Document Type: Article

References (17)

1. Turaga KK, Pappas SG, Gamblin T: Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012;19:1379-1385.
2. Carr NJ, Cecil TD, Mohamed F, et al: A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: The results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol 2016;40:14-26.
3. Verwaal VJ, Bruin S, Boot H, et al: 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-2432.
4. Tejani MA, ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB 3rd, Schrag D, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJ: Systemic therapy for advanced appendiceal adenocarcinoma: An analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw 2014;12:1123-1130.
5. Wilson CH, McIntyre RE, Arends MJ, Adams DJ: The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 2010;29:4567-4575.
6. Gilmartin AG, Bleam MR, Groy A, et al: GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
7. Liu X, Mody K, de Abreu FB, et al: Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem 2014;60:1004-1011.
8. Noguchi R, Yano H, Gohda Y, et al: Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer Med 2015;4:1809-1816.
9. Hara K, Saito T, Hayashi T, et al: A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. Pathol Res Pract 2015;211:657-664.
10. Alakus H, Babicky ML, Ghosh P, et al: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med 2014;6:43.
11. Nishikawa G, Sekine S, Ogawa R, Matsubara A, Mori T, Taniguchi H, Kushima R, Hiraoka N, Tsuta K, Tsuda H, Kanai Y: Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 2013;108:951-958.
12. Singhi AD, Davison JM, Choudry HA, et al: GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Hum Pathol 2014;45: 1737-1743.
13. Mariot V, Wu JY, Aydin C, et al: Potent constitutive cyclic AMP-generating activity of XLαs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. Bone 2011;48:312-320.
14. Landis CA, Masters SB, Spada A, et al: GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692-696.
15. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
16. Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D, DeMarini DJ, Gardner O, Crist W, Patel K: Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol 2016;77:807-817.
17. Infante JR, Fecher LA, Falchook GS, et al: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol 2012;13:773-781.